XML 22 R12.htm IDEA: XBRL DOCUMENT v3.6.0.2
Note 7 - Stockholders' Equity
6 Months Ended
Dec. 31, 2016
Notes to Financial Statements  
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]
7.
     
Stockholders’ Equity
 
Common Stock
On
August
3,
2016,
the Company sold
600,000
shares of common stock at a price of
$4.10
per share. The net proceeds to the Company from the sale and issuance of the shares, after deducting the offering expenses borne by the Company of
$369,
were
$2,091.
 
 
In
July
2016,
the compensation committee of the board of directors granted
118,288
shares of fully vested common stock to employees in partial payment of their earned amounts under the Company’s
2016
short term incentive plan. The election was made by some of the employees to satisfy the applicable federal income tax withholding obligation by a net share settlement, pursuant to which the Company withheld
46,879
shares and used the deemed proceeds from those shares to pay the income tax withholding. The net share settlement is deemed to be a repurchase by the Company of its common stock.
 
Stock Based Compensation
The Company recorded stock-based compensation of
$735
and
$1,033
for the
three
and
six
months ended
December
31,
2016,
and
($39)
and
$304
for the
three
and
six
months ended
December
31,
2015.
 
Upon the separation with the Company’s CEO in
November
2016,
in accordance with his employment agreement, all outstanding options and restricted stock awards immediately vested. As a result, the Company recognized
$539
of stock compensation expense in general and administrative as the vesting accelerated on
72,496
options and
79,720
restricted stock awards. Additionally, the terms of the options were modified upon the CEO’s termination such that the options were deemed to be exercisable for the entire period of the option versus expiring
90
days from the date of termination. There was no incremental compensation cost recorded for this modification as the fair-value-based measure of the modified award on the date of modification was less than the fair-value-based measure of the original award immediately before the modification.
 
The following is a summary of option activity for the Company’s stock option plans:
 
   
Number of
Shares
   
Weighted-
Average
Exercise
Price
   
Weighted-
Average
Remaining
Contractual
Life
   
Aggregate
Intrinsic
Value
 
                                 
Outstanding at June 30, 2016
   
104,378
    $
14.85
     
 
     
 
 
                                 
Granted
   
223,825
    $
2.93
     
 
     
 
 
Forfeited
   
(3,835
)   $
16.15
     
 
     
 
 
Expired
   
(2,500
)   $
18.46
     
 
     
 
 
                                 
Outstanding at December 31, 2016
   
321,868
    $
6.52
     
6.3
    $
129
 
                                 
Vested and Expected to Vest at December 31, 2016
   
285,743
    $
6.88
     
6.2
    $
111
 
                                 
Exercisable at December 31, 2016
   
157,553
    $
9.58
     
5.9
    $
49
 
 
In
December
2016,
the compensation committee of the board of directors granted
50,000
options to the Company’s interim CEO. The options have an exercise price of
$2.91,
the closing price on the date of grant, they vest in
five
equal installments on each of
December
16,
2016,
February
4,
2017,
May
4,
2017,
August
4,
2017
and
November
4,
2017
and have a
seven
year life. As the options were granted out of the
2016
Equity Incentive Plan
(“2016
Plan”), they will not be exercisable until the
2016
Plan is approved by the stockholders, which approval must be received by
July
7,
2017.
 
On
July
7,
2016,
the compensation committee of the board of directors granted
156,100
options to various employees. The options have an exercise price of
$2.86,
the closing price on the date of grant, they vest ratably every
six
months over a
three
year period and have a
seven
year life. As the options were granted out of the
2016
Equity Incentive Plan
(“2016
Plan”), they will not be exercisable until the
2016
Plan is approved by the stockholders, which approval must be received by
July
7,
2017.
 
The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock. There were
no
options exercised during the
six
months ended
December
31,
2016
and
2015.
 
The fair value of the Company’s stock options granted for the
six
months ended
December
31,
2016
was estimated using the following weighted-average assumptions:
 
Expected life (years)
   
4.2
 
Risk-free interest rate
   
1.1
%
Expected volatility
   
102.7
%
Dividend yield
   
0
%
 
At
December
31,
2016,
the total compensation cost related to options granted but not yet recognized was
$259
which will be amortized over a weighted-average period of approximately
two
years.
 
 
Common Stock Restricted
Units
The following is a summary of restricted stock activity during the
six
months ended
December
31,
2016:
 
           
Weighted
Average
 
   
Number of
Shares
   
Grant Date
Fair Value
 
Balance at June 30, 2016
   
63,566
    $
14.96
 
Granted
   
98,417
    $
4.97
 
Vested
   
(95,902
)   $
10.85
 
Forfeited
   
(933
)   $
26.37
 
Outstanding at December 31, 2016
   
65,148
    $
5.26
 
 
On
July
26,
2016,
the compensation committee of the board of directors granted
98,417
shares of restricted stock to
eight
employees. The shares will fully vest on
July
1,
2017
provided that the individual is employed by the Company as of such date. If the employee is terminated without cause prior to
July
1,
2017
the shares vest immediately. Two of the
eight
employees were terminated during the quarter ended
December
31,
2016,
as such,
35,902
shares vested.
 
Warrants
A summary of warrant activity for the
six
months ended
December
31,
2016
follows:
 
   
Number of
Shares
   
Weighted-
Average
Exercise Price
Per Share
 
Beginning balance
   
4,828,721
    $
9.37
 
Warrants granted
   
--
     
--
 
Warrants canceled
   
--
     
--
 
Warrants exercised
   
--
     
--
 
                 
Outstanding at December 31, 2016
   
4,828,721
    $
9.37
 
                 
Exercisable at December 31, 2016
   
4,130,192
    $
9.60
 
 
At
December
31,
2016,
the total intrinsic value of warrants outstanding and exercisable was
$0.